Book contents
- The Movement Disorders Prescriber’s Guide to Parkinson’s Disease
- Reviews
- The Movement Disorders Prescriber’s Guide to Parkinson’s Disease
- Copyright page
- Contents
- Foreword
- Abbreviations
- Introduction
- Amantadine
- Amitriptyline
- Apomorphine Hydrochloride Subcutaneous Infusion
- Apomorphine Hydrochloride Subcutaneous Injection
- Apomorphine Hydrochloride Sublingual Film
- Botulinum Toxin
- Citalopram
- Clonazepam
- Clozapine
- Desipramine
- Domperidone
- Donepezil
- Droxidopa
- Entacapone
- Fludrocortisone
- Glycopyrrolate
- Istradefylline
- Levodopa–Benserazide
- Levodopa–Carbidopa
- Levodopa–Carbidopa Intestinal Gel
- Levodopa–Carbidopa–Entacapone Intestinal Gel
- Levodopa, Inhaled
- Lubiprostone
- Macrogol
- Melatonin
- Memantine
- Midodrine
- Mirabegron
- Mirtazapine
- Modafinil
- Naltrexone
- Nortriptyline
- Opicapone
- Oxybutynin
- Pimavanserin
- Piribedil
- Pramipexole*
- Quetiapine
- Rasagiline
- Rivastigmine
- Ropinirole
- Rotigotine
- Safinamide
- Selegiline
- Sildenafil
- Solifenacin
- Tolcapone
- Tolterodine
- Trihexyphenidyl
- Venlafaxine
- Zonisamide
- Levodopa Dose Equivalence in Parkinson’s
- Subcutaneous Foslevodopa Foscarbidopa infusion
- Index
- References
Sildenafil
Published online by Cambridge University Press: 20 February 2025
Book contents
- The Movement Disorders Prescriber’s Guide to Parkinson’s Disease
- Reviews
- The Movement Disorders Prescriber’s Guide to Parkinson’s Disease
- Copyright page
- Contents
- Foreword
- Abbreviations
- Introduction
- Amantadine
- Amitriptyline
- Apomorphine Hydrochloride Subcutaneous Infusion
- Apomorphine Hydrochloride Subcutaneous Injection
- Apomorphine Hydrochloride Sublingual Film
- Botulinum Toxin
- Citalopram
- Clonazepam
- Clozapine
- Desipramine
- Domperidone
- Donepezil
- Droxidopa
- Entacapone
- Fludrocortisone
- Glycopyrrolate
- Istradefylline
- Levodopa–Benserazide
- Levodopa–Carbidopa
- Levodopa–Carbidopa Intestinal Gel
- Levodopa–Carbidopa–Entacapone Intestinal Gel
- Levodopa, Inhaled
- Lubiprostone
- Macrogol
- Melatonin
- Memantine
- Midodrine
- Mirabegron
- Mirtazapine
- Modafinil
- Naltrexone
- Nortriptyline
- Opicapone
- Oxybutynin
- Pimavanserin
- Piribedil
- Pramipexole*
- Quetiapine
- Rasagiline
- Rivastigmine
- Ropinirole
- Rotigotine
- Safinamide
- Selegiline
- Sildenafil
- Solifenacin
- Tolcapone
- Tolterodine
- Trihexyphenidyl
- Venlafaxine
- Zonisamide
- Levodopa Dose Equivalence in Parkinson’s
- Subcutaneous Foslevodopa Foscarbidopa infusion
- Index
- References
Summary
Sildenafil citrate (5-[2-ethoxy-5-(4-methylpiperazin-1-ylsulfonyl)phenyl]-1,6-dihydro-1-methyl-3-propylpyrazolo[4,3-d]pyrimidin-7-one citrate; 1-{[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl}-4-methylpiperazone citrate) is a phosphodiesterase-5 inhibitor with a molecular weight of 666.7 and a molecular formula of C22H30N6O4S,C6H8O7.
- Type
- Chapter
- Information
- The Movement Disorders Prescriber's Guide to Parkinson's Disease , pp. 459 - 472Publisher: Cambridge University PressPrint publication year: 2025
References
Suggested Reading
Bernard, BA, Metman, LV, Levine, L, Ouyang, B, Leurgans, S, Goetz, CG. Sildenafil in the treatment of erectile dysfunction in Parkinson’s disease. Mov Disord Clin Pract 2017; 4(3): 412–415.CrossRefGoogle ScholarPubMed
Hussain, IF, Brady, CM, Swinn, MJ, Mathias, CJ, Fowler, CJ. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson’s disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 2001; 71(3): 371–374.CrossRefGoogle ScholarPubMed
Raffaele, R, Vecchio, I, Giammusso, B, Morgia, G, Brunetto, MB, Rampello, L. Efficacy and safety of fixed-dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson’s disease. Eur Urol 2002; 41(4): 382–386.CrossRefGoogle ScholarPubMed
Zesiewicz, TA, Helal, M, Hauser, RA. Sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men with Parkinson’s disease. Mov Disord 2000; 15(2): 305–308.3.0.CO;2-W>CrossRefGoogle ScholarPubMed
References
AHFS Drug information, 2012. Bethesda: American Society of Health-System Pharmacists. Accessed on 31 December 2022 via www.medicinescomplete.com.Google Scholar
Bronner, G, Vodušek, DB. Management of sexual dysfunction in Parkinson’s disease. Ther Adv Neurol Disord 2011; 4(6): 375–383.CrossRefGoogle ScholarPubMed
Joint Formulary Committee. British National Formulary (online). London: BMJ Group and Pharmaceutical Press. Accessed on 31 December 2022 via www.medicinescomplete.com.Google Scholar
Salonia, A, Rigatti, P, Montorsi, F. Sildenafil in erectile dysfunction: a critical review. Curr Med Res Opin 2003; 19(4): 241–262.CrossRefGoogle ScholarPubMed
Sildenafil. In: Brayfield, A (Ed.), Martindale: The Complete Drug Reference. London: The Royal Pharmaceutical Society of Great Britain. Accessed on 31 December 2022 via www.medicinescomplete.com.Google Scholar
Sildenafil. In: DRUGDEX® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Accessed on 31 December 2022 via www.micromedexsolutions.com.Google Scholar
Smith, BP, Babos, M. Sildenafil. In: StatPearls. 2022, StatPearls Publishing. Copyright © 2022, Treasure Island (FL): StatPearls Publishing LLC.Google Scholar
Summary of product characteristics – Viagra 25 mg film-coated tablets. Upjohn UK Limited. Electronic Medicines Compendium: Viagra 25 mg film-coated tablets – summary of product characteristics (SmPC) – (emc). Accessed on 31 December 2022 via www.medicines.org.uk.Google Scholar